Dr. Li is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
530 East 74th Street
New York, NY 10021
Education & Training
University of SydneyMPH, 2012 - 2014
University of New South Wales Faculty of MedicineClass of 2006
Certifications & Licensure
NY State Medical License 2015 - 2025
Clinical Trials
- Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers Start of enrollment: 2016 Feb 01
- DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer Start of enrollment: 2018 May 21
- A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors Start of enrollment: 2020 Feb 24
- Join now to see all
Publications & Presentations
PubMed
- EGFR-directed antibodies promote HER2 ADC internalization and efficacy.Avantika Gupta, Flavia Michelini, Hong Shao, Celine Yeh, Joshua Z Drago
Cell Reports. Medicine. 2024-11-19 - 1 citationsAutomated real-world data integration improves cancer outcome prediction.Justin Jee, Christopher Fong, Karl Pichotta, Thinh Ngoc Tran, Anisha Luthra
Nature. 2024-11-06 - Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.Erika P Hamilton, Gerald S Falchook, Judy S Wang, Siqing Fu, Amit M Oza
Targeted Oncology. 2024-11-01
Lectures
- Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.2019 ASCO Annual Meeting - 6/1/2019
- A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Authored Content
- We Need a Global System for Testing and Approving Cancer TreatmentsOctober 2022
Press Mentions
AstraZeneca Names a MSK Leader to Global Cancer PostNovember 25th, 2024- MSK Research Highlights, May 18, 2023May 18th, 2023
- 2-Year Follow-up Shows Sotorasib Significantly Prolongs Survival in Patients with Non-Small Cell Lung CancerApril 30th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
